Patent ID: 11970536
Assignee: AKAMIS BIO LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A replication capable group B oncolytic adenovirus selected from the group consisting of Ad 11 and enadenotucirev (EnAd), wherein the adenovirus comprises a transgene encoding an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), and the gene encoding said antibody or binding fragment is located between the adenoviral gene L5 and the gene E4, and the encoded antibody further comprises a transmembrane domain or a GPI anchor, wherein the transgene encoding the anti-CD3 antibody or binding fragment is under the control of the endogenous major late promoter of the adenovirus, wherein the adenovirus encodes at least one further transgene, wherein the further transgene(s) encode(s) a protein independently selected from a cytokine, a chemokine, an antagonistic antibody molecule or binding fragment thereof, an agonistic antibody molecule or binding fragment thereof, and combinations thereof, and said one or more further transgenes are between the gene E4 and the gene L5 under the control of the major late promoter of the adenovirus, and wherein the anti-CD3 antibody or binding fragment thereof and protein encoded by the further transgene are expressed independently anchored at the surface of the cancer cell, wherein the adenovirus does not encode a B7 protein or an active fragment thereof.